All In Biotech

Drug Trial Radar · NCT00648531

Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg

Single-Dose Fasting In Vivo Bioequivalence Study of Balsalazide Disodium Capsules (750 mg; Mylan) and Colazal® Capsules (750 mg; Salix) in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

May 2004

Primary completion

May 2004

Study completion May 2004

Sponsor

Lead sponsor
Mylan Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Apr 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to investigate the bioequivalence of Mylan balsalazide disodium 750 mg capsules and Salix Colazal® 750 mg capsules following a single, oral 2250 mg (3 x 750 mg) dose administration under fasting conditions.

Conditions

  • Healthy

Interventions

  • Balsalazide Disodium Capsules 750 mgDrug

    3x750mg, single dose fasting

  • Colazal® Capsules 750 mgDrug

    3x750mg, single dose fasting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BioequivalenceTime frame: within 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRACS Institute, Ltd.

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.